Adial Pharmaceuticals Stock Net Income
| ADIL Stock | USD 0.23 0.01 4.55% |
As of the 25th of January, Adial Pharmaceuticals shows the Standard Deviation of 3.81, risk adjusted performance of (0.11), and Mean Deviation of 2.89. Adial Pharmaceuticals technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices. Please confirm Adial Pharmaceuticals coefficient of variation, treynor ratio, as well as the relationship between the Treynor Ratio and skewness to decide if Adial Pharmaceuticals is priced correctly, providing market reflects its regular price of 0.23 per share. As Adial Pharmaceuticals appears to be a penny stock we also recommend to validate its jensen alpha numbers.
Adial Pharmaceuticals' financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing Adial Pharmaceuticals' valuation are provided below:There are over one hundred nineteen available fundamental signals for Adial Pharmaceuticals, which can be analyzed over time and compared to other ratios. We recommend to validate Adial Pharmaceuticals' prevailing fundamental drivers against the all of the trends between 2010 and 2026. Market Cap is expected to rise to about 22.5 M this year. Enterprise Value is expected to rise to about 18.9 M this year This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools. | Last Reported | Projected for Next Year | ||
| Net Loss | -11.9 M | -12.5 M | |
| Net Loss | -17.5 M | -16.6 M | |
| Net Loss | -11.9 M | -12.5 M | |
| Net Loss | (0.64) | (0.67) | |
| Net Income Per E B T | 1.06 | 0.85 |
Adial | Net Income | Build AI portfolio with Adial Stock |
Latest Adial Pharmaceuticals' Net Income Growth Pattern
Below is the plot of the Net Income of Adial Pharmaceuticals over the last few years. Net income is one of the most important fundamental items in finance. It plays a large role in Adial Pharmaceuticals financial statement analysis. It represents the amount of money remaining after all of Adial Pharmaceuticals operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue. It is Adial Pharmaceuticals' Net Loss historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Adial Pharmaceuticals' overall financial position and show how it may be relating to other accounts over time.
| View | Last Reported (13.2 M) | 10 Years Trend |
|
Net Income |
| Timeline |
Adial Net Income Regression Statistics
| Arithmetic Mean | (6,720,841) | |
| Coefficient Of Variation | (92.91) | |
| Mean Deviation | 5,564,602 | |
| Median | (7,001,890) | |
| Standard Deviation | 6,244,151 | |
| Sample Variance | 39T | |
| Range | 19M | |
| R-Value | (0.81) | |
| Mean Square Error | 14.4T | |
| R-Squared | 0.65 | |
| Significance | 0.000087 | |
| Slope | (999,131) | |
| Total Sum of Squares | 623.8T |
Adial Net Income History
Other Fundumenentals of Adial Pharmaceuticals
| Net Income From Continuing Ops | ||
| Net Income Applicable To Common Shares | ||
| Net Income Per Share | ||
| Net Income Per E B T |
Adial Pharmaceuticals Net Income component correlations
Adial Net Income Driver Correlations
Understanding the fundamental principles of building solid financial models for Adial Pharmaceuticals is extremely important. It helps to project a fair market value of Adial Stock properly, considering its historical fundamentals such as Net Income. Since Adial Pharmaceuticals' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Adial Pharmaceuticals' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Adial Pharmaceuticals' interrelated accounts and indicators.
Click cells to compare fundamentals
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Adial Pharmaceuticals. If investors know Adial will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Adial Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Adial Pharmaceuticals is measured differently than its book value, which is the value of Adial that is recorded on the company's balance sheet. Investors also form their own opinion of Adial Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Adial Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Adial Pharmaceuticals' market value can be influenced by many factors that don't directly affect Adial Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Adial Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Adial Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Adial Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Adial Pharmaceuticals 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Adial Pharmaceuticals' stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Adial Pharmaceuticals.
| 10/27/2025 |
| 01/25/2026 |
If you would invest 0.00 in Adial Pharmaceuticals on October 27, 2025 and sell it all today you would earn a total of 0.00 from holding Adial Pharmaceuticals or generate 0.0% return on investment in Adial Pharmaceuticals over 90 days. Adial Pharmaceuticals is related to or competes with Neurosense Therapeutics, Acurx Pharmaceuticals, Matinas BioPharma, Brainstorm Cell, Aprea Therapeutics, HCW Biologics, and Kiora Pharmaceuticals. Adial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for ... More
Adial Pharmaceuticals Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Adial Pharmaceuticals' stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Adial Pharmaceuticals upside and downside potential and time the market with a certain degree of confidence.
| Information Ratio | (0.18) | |||
| Maximum Drawdown | 16.67 | |||
| Value At Risk | (6.25) | |||
| Potential Upside | 5.56 |
Adial Pharmaceuticals Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Adial Pharmaceuticals' investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Adial Pharmaceuticals' standard deviation. In reality, there are many statistical measures that can use Adial Pharmaceuticals historical prices to predict the future Adial Pharmaceuticals' volatility.| Risk Adjusted Performance | (0.11) | |||
| Jensen Alpha | (0.72) | |||
| Total Risk Alpha | (0.97) | |||
| Treynor Ratio | (0.42) |
Adial Pharmaceuticals January 25, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | (0.11) | |||
| Market Risk Adjusted Performance | (0.41) | |||
| Mean Deviation | 2.89 | |||
| Coefficient Of Variation | (629.81) | |||
| Standard Deviation | 3.81 | |||
| Variance | 14.51 | |||
| Information Ratio | (0.18) | |||
| Jensen Alpha | (0.72) | |||
| Total Risk Alpha | (0.97) | |||
| Treynor Ratio | (0.42) | |||
| Maximum Drawdown | 16.67 | |||
| Value At Risk | (6.25) | |||
| Potential Upside | 5.56 | |||
| Skewness | 0.1112 | |||
| Kurtosis | 0.2047 |
Adial Pharmaceuticals Backtested Returns
Adial Pharmaceuticals secures Sharpe Ratio (or Efficiency) of -0.16, which signifies that the company had a -0.16 % return per unit of risk over the last 3 months. Adial Pharmaceuticals exposes twenty-two different technical indicators, which can help you to evaluate volatility embedded in its price movement. Please confirm Adial Pharmaceuticals' Mean Deviation of 2.89, standard deviation of 3.81, and Risk Adjusted Performance of (0.11) to double-check the risk estimate we provide. The firm shows a Beta (market volatility) of 1.47, which signifies a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Adial Pharmaceuticals will likely underperform. At this point, Adial Pharmaceuticals has a negative expected return of -0.64%. Please make sure to confirm Adial Pharmaceuticals' total risk alpha and the relationship between the skewness and period momentum indicator , to decide if Adial Pharmaceuticals performance from the past will be repeated at some point in the near future.
Auto-correlation | 0.78 |
Good predictability
Adial Pharmaceuticals has good predictability. Overlapping area represents the amount of predictability between Adial Pharmaceuticals time series from 27th of October 2025 to 11th of December 2025 and 11th of December 2025 to 25th of January 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Adial Pharmaceuticals price movement. The serial correlation of 0.78 indicates that around 78.0% of current Adial Pharmaceuticals price fluctuation can be explain by its past prices.
| Correlation Coefficient | 0.78 | |
| Spearman Rank Test | 0.47 | |
| Residual Average | 0.0 | |
| Price Variance | 0.0 |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Based on the recorded statements, Adial Pharmaceuticals reported net income of (13.2 Million). This is 103.87% lower than that of the Pharmaceuticals sector and 118.84% lower than that of the Health Care industry. The net income for all United States stocks is 102.31% higher than that of the company.
Adial Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Adial Pharmaceuticals' direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Adial Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Adial Pharmaceuticals by comparing valuation metrics of similar companies.Adial Pharmaceuticals is currently under evaluation in net income category among its peers.
Adial Pharmaceuticals Current Valuation Drivers
We derive many important indicators used in calculating different scores of Adial Pharmaceuticals from analyzing Adial Pharmaceuticals' financial statements. These drivers represent accounts that assess Adial Pharmaceuticals' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Adial Pharmaceuticals' important valuation drivers and their relationship over time.
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 (projected) | ||
| Market Cap | 50.2M | 5.8M | 2.6M | 18.8M | 21.6M | 22.5M | |
| Enterprise Value | 44.4M | 2.1M | (177.2K) | 15.0M | 17.3M | 18.9M |
Adial Pharmaceuticals Institutional Holders
Institutional Holdings refers to the ownership stake in Adial Pharmaceuticals that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Adial Pharmaceuticals' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Adial Pharmaceuticals' value.| Shares | Sbi Securities Co Ltd | 2025-06-30 | 1.3 K | Wells Fargo & Co | 2025-06-30 | 160 | Bank Of America Corp | 2025-06-30 | 73.0 | Abound Wealth Management | 2025-06-30 | 27.0 | Morgan Stanley - Brokerage Accounts | 2025-06-30 | 9.0 | Citadel Advisors Llc | 2025-03-31 | 0.0 | Renaissance Technologies Corp | 2025-03-31 | 0.0 | Virtu Financial Llc | 2025-06-30 | 0.0 | Cambridge Invest Research Advisors, Inc. | 2025-03-31 | 0.0 | Geode Capital Management, Llc | 2025-06-30 | 68.8 K | Manchester Capital Management Llc | 2025-06-30 | 48.1 K |
Adial Fundamentals
| Return On Equity | -1.55 | ||||
| Return On Asset | -0.79 | ||||
| Current Valuation | 1.82 M | ||||
| Shares Outstanding | 27.78 M | ||||
| Shares Owned By Insiders | 2.08 % | ||||
| Shares Owned By Institutions | 3.40 % | ||||
| Number Of Shares Shorted | 385.8 K | ||||
| Price To Earning | (1.88) X | ||||
| Price To Book | 1.43 X | ||||
| EBITDA | (8.28 M) | ||||
| Net Income | (13.2 M) | ||||
| Cash And Equivalents | 9.16 M | ||||
| Cash Per Share | 0.35 X | ||||
| Total Debt | 975.86 K | ||||
| Debt To Equity | 0.03 % | ||||
| Current Ratio | 5.32 X | ||||
| Book Value Per Share | 0.19 X | ||||
| Cash Flow From Operations | (6.92 M) | ||||
| Short Ratio | 1.24 X | ||||
| Earnings Per Share | (0.60) X | ||||
| Target Price | 2.17 | ||||
| Beta | 1.2 | ||||
| Market Capitalization | 6.43 M | ||||
| Total Asset | 5.04 M | ||||
| Retained Earnings | (82 M) | ||||
| Working Capital | 3.08 M | ||||
| Current Asset | 1.02 M | ||||
| Current Liabilities | 452.53 K | ||||
| Net Asset | 5.04 M |
About Adial Pharmaceuticals Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Adial Pharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Adial Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Adial Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Prophet is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ProphetCheck out Adial Pharmaceuticals Piotroski F Score and Adial Pharmaceuticals Altman Z Score analysis. For more information on how to buy Adial Stock please use our How to buy in Adial Stock guide.You can also try the Idea Optimizer module to use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio .
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Adial Pharmaceuticals. If investors know Adial will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Adial Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Adial Pharmaceuticals is measured differently than its book value, which is the value of Adial that is recorded on the company's balance sheet. Investors also form their own opinion of Adial Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Adial Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Adial Pharmaceuticals' market value can be influenced by many factors that don't directly affect Adial Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Adial Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Adial Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Adial Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.